New programs respond to unmet needs described by the GBM community
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today it will deliver new programs to support the glioblastoma (GBM) community during Brain Tumor Awareness Month. Last year, Novocure held events to listen to the needs of the GBM community, learn how to better support patients and caregivers, and improve connectivity within the community. This year’s programs, a direct result of last year’s efforts, aim to raise awareness of glioblastoma, the most common and aggressive form of primary brain cancer in adults.
“Novocure actively engaged with the GBM community to determine what resources they felt they needed most and how we might help meet their needs,” said Pritesh Shah, Senior Vice President, Americas, Novocure. “Making good on the promise of turning their insights into actions is incredibly important to us. We are excited to bring these new programs to life. We know living with GBM has a profound impact on patients, caregivers and their loved ones. We are proud to deliver resources that offer insights and encouragement from the people who are living GBM every day.”
Novocure will kick off Brain Tumor Awareness Month with the introduction of a new online resource: GBMcommunity.com. This site features a mosaic of videos and images from people affected by GBM, offering messages of hope and inspiration and encouraging others to share their voices. The website also provides an overview of GBM and links to resources and advocacy groups.
Novocure will also help to amplify the GBM community’s voice with social media-led initiatives. Efforts include sponsoring a Thunderclap, a tool using social media accounts to collectively support and share a message simultaneously. Novocure will also be a sponsor at 11 advocacy and locally led walks from California to New York. In addition, Novocure is sponsoring the Frankly Speaking About Cancer radio show to help raise awareness of GBM.
About Glioblastoma Multiforme
Glioblastoma, also called glioblastoma multiforme, or GBM, is a type of primary brain cancer. This means that GBM tumors begin in the brain, rather than traveling to the brain from other parts of the body, such as the lungs or breasts. Approximately 12,500 GBM tumors, or tumors that may transform into GBM, are diagnosed in the U.S. each year.GBM is the most common type of primary brain cancer in adults. It is more likely to appear in older adults and to affect men than women. GBM is one of the deadliest forms of cancer, with patients typically not surviving beyond 15 months after diagnosis.
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquarter in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Quarterly Report on Form 10-Q filed on October 27, 2015 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investor Contact:
Ashley Cordova, 212-767-7558